Global Pancreatic Cancer Drugs Market to Exceed $1.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Pancreatic Cancer Drugs market. The world market for pancreatic cancer drugs is projected to exceed $1.2 billion by the year 2015. The market is driven by sales of Gemzar, the standard treatment for pancreatic cancer, as well as the only other approved therapy, Tarceva. The only potential option for cure is surgery, for which just about a fifth of patients diagnosed with pancreatic cancer are generally suitable.

Pancreatic Cancer Drugs: A Global Market Report

Pancreatic cancer is typically very aggressive in nature, responds rather inadequately to treatment, and is generally diagnosed when it has already reached the locally advanced or metastatic stage. The rates of mortality tend to be high, and there exists no therapy that is shown to significantly improve survival. Only a few systemic treatments are available, and just about 20% of the patients diagnosed with a resectable disease are eligible to receive the systemic therapy.

Eli Lilly's Gemzar (Gemcitabine) is the current gold standard of care for locally advanced and metastatic disease, with a dominance that is undisputed despite a median survival of less than 6 months and rate of one-year survival of around 18%, as stated by the new market research report on Pancreatic cancer drugs. Though the odds of survival are somewhat better in other forms of cancer, the rate of five-year survival for the most common form of pancreatic cancer, Adenocarcinoma of the pancreas is less than 5%, with majority of patients surviving just a few months.

A macro level perspective of the drug development projects would highlight that most clinical trials have studied combinations with Gemcitabine as a mainstay drug and none till date have been able to provide significantly superior outcomes than Gemcitabine alone. Even the combinations of biological agents and gemcitabine have not been successful. There is a kind of gemcitabine fixation, with researchers unable to think beyond the gemcitabine box, even as the disease continues to claim several thousands of lives every year.

Competition in the global pancreatic cancer drugs market is virtually non-existent where Eli Lilly's Gemzar (Gemcitabine) and Genentech/ OSI Pharmaceuticals/ Roche's Tarceva (Erlotinib) are the only therapies indicated for the treatment of pancreatic cancer. Of the two, Gemzar is the most widely prescribed therapeutic.

The report titled "Pancreatic Cancer Drugs: A Global Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of the market, competitive scenario, pipeline drugs, research & development, regulatory submissions/approvals, and recent industry activity.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website